Does Selling Generic GLP-1 Medications Affect Diabetics' Access to Branded Versions?

One of the biggest misconceptions about GLP-1 medications like Semaglutide and Tirzepatide is that their availability for weight loss treatments is taking essential drugs away from diabetes patients. While Semaglutide is the active ingredient in both Wegovy and Ozempic, it’s important to clarify that Freya does not sell these branded versions. Instead, we provide generic Semaglutide, which is equally effective but does not deplete the supply of brand-name drugs like Ozempic.

Increasing Supply, Not Draining It

By offering generic versions of these medications, Freya is actually expanding access to GLP-1 treatments for both diabetes and weight loss. This creates new supply channels that aren’t reliant on the limited stock of branded drugs. By offering this generic medication, Freya alleviates pressure on the supply of Ozempic and other branded versions that are primarily used by diabetes patients.

The Same Applies to Tirzepatide

The same applies to Tirzepatide, the active ingredient in Mounjaro. Freya provides the generic form of this medication, ensuring that the supply for diabetes patients remains intact. Through this approach, we are giving patients new opportunities to manage their weight without taking medication from those who need it for diabetes management.

In summary, by offering generic Semaglutide and Tirzepatide, Freya is actually contributing to the supply of these life-changing medications, not diminishing it. This allows more people to access the health benefits of these treatments while ensuring that diabetes patients receive the care they need.